Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Travere Therapeutics (RTRX) News Today

Travere Therapeutics logo

RTRX Latest News

Travere Therapeutics, Inc. (TVTX): A Bull Case Theory
7TVTX : Earnings Outlook For Travere Therapeutics
Travere Therapeutics
Travere Therapeutics Q3 2025 Earnings Preview
Travere Therapeutics Inc.
Travere Therapeutics price target lowered to $30 from $32 at Scotiabank
Travere Therapeutics price target raised to $47 from $45 at Canaccord
Travere Therapeutics price target lowered to $27 from $31 at BofA
Travere Therapeutics price target raised to $31 from $29 at BofA
Travere Therapeutics price target raised to $44 from $42 at JPMorgan
Get Travere Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RTRX Media Mentions By Week

RTRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RTRX
News Sentiment

0.00

0.60

Average
Medical
News Sentiment

RTRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RTRX Articles
This Week

1

0

RTRX Articles
Average Week

Get the Latest News and Ratings for RTRX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NASDAQ:RTRX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners